Authors: Cristino L , Bisogono T , Di Marzo
Here is what this research means for you :
Anecdotal evidence is that cannabis preparations have medical benefits together with the discovery of the psychotropic plant-cannabinoid Δ -tetrahydrocannabinol (THC). It started efforts to develop THC-based therapeutics.
Disappointment has marked these efforts, especially concerning the unwanted response as a result of activation of cannabinoid receptor 1 (CB1) which have limited the therapeutic use of drugs that activate or inactivate this receptor.
While the discovery of CB2 and its Endogenous receptor ligands (Endocannabinoids) raised new possibilities for safe targeting of this system.
Clinical success has been limited, complicated by the discovery of an expanded endocannabinoid system – known as the Endocannabinoidome.
is a biological system composed of endocannabinoids, which are Inhibitory neurotransmitters, that bind to cannabinoid receptors (CBRs), and cannabinoid receptor proteins that are expressed throughout the vertebrate central nervous system CNS (including the brain) and peripheral nervous system PNS. That includes several mediators that are biochemically related to the Endocannabinoids, and their receptors and metabolic enzymes.
The approvals of Nabiximols, a mixture of THC and the non-psychotropic cannabidiol, to treat spasticity and neuropathic pain in multiple sclerosis, and of purified botanical cannabidiol to treat otherwise untreatable forms of pediatric epilepsy, have brought the therapeutic use of cannabinoids and endocannabinoids in neurological disorders into the limelight.
. In this Review, we provide an overview of the endocannabinoid system and the endocannabinoidome before discussing their involvement in and clinical relevance to a variety of neurological disorders, including Parkinson’s disease, Alzheimer’s disease, Huntington disease, multiple sclerosis, amyotrophic lateral sclerosis. traumatic brain injury, stroke , epilepsy, and glioblastoma